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Abstract Thapsigargin, a selective inhibitor of the endoplasmic 
reticulum Ca 2÷ pump, has been shown to deplete inositol-l,4,5- 
trisphosphate-sensitive Ca 2+ stores. Here we report that when 
thapsigargin was introduced to serum-stimulated human fibro- 
blasts at a time point just before the GI/S boundary, it completely 
inhibited expression of cyclin A, activation of p33 c°K2 cyclin- 
dependent kinase and initiation of DNA synthesis. In contrast, the 
Ca 2÷ mobilizing ionophore ionomycin was without effect. These 
findings indicate that Ca 2+ inside the inositol-l,4,5-trisphosphate- 
sensitive Ca 2÷ stores plays a pivotal role for traverse across the 
GIIS transition point. 
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whether or not IP3-sensitive Ca 2+ stores are involved in the 
other phases of cell cycle progression is not addressed in these 
studies. Also, molecular mechanisms underlying thapsigargin- 
induced inhibition of DNA synthesis are not well resolved yet. 
In the present study, we explored a possibility that functional 
InsP3-sensitive Ca2+stores are required for cell cycle progres- 
sion at points later than the G0/G1 border. Further, we tried 
to determine whether IP3-sensitive Ca 2+ stores play any role in 
the activation of a cyclin-dependent protein kinase which is 
critical for cell cycle progression. We found that thapsigargin 
completely inhibits DNA synthesis when it is added to cells just 
before the GI/S boundary. The results of the present study 
indicate that the mechanism of this thapsigargin-mediated GI/S 
block involves complete suppressions of cyclin A expression 
and p33 cD~2 kinase activation. 
1. Introduction 2. Materials and methods 
It has been widely recognized that stimulation of quiescent 
cells with a variety of growth factors or mitogens induces a 
transient rise in the intracellular free Ca 2+ concentration 
([Ca2+]~), through rapid Ca 2÷ mobilization from both inositol- 
1,4,5-trisphosphate (InsP3)-sensitive intracellular stores and 
outside of cells [1-5]. The increase in [Ca2÷]i is postulated to 
serve as a mitogenic signalling for re-entry into the cell cycle 
at the G0/G1 border [6,7]. Recently, Gill and his colleagues 
[8-10] have demonstrated that thapsigargin, which is a selective 
inhibitor ofendoplasmic reticulum Ca 2+ pump [11] and depletes 
InsP3-sensitive Ca 2+ stores [12,13], potently inhibits cell prolif- 
eration. In their experiments, density-arrested DDT1MF-2 
smooth muscle cells were growth-stimulated by trypsinizing 
and replating into fresh growth media. When thapsigargin was 
added to ceils at the time of plating, it completely inhibited the 
following DNA synthesis and cell division, without altering cell 
morphology or viability. The thapsigargin dose-response curve 
for inhibition of DNA synthesis was comparable to that for 
inhibition of Ca 2÷ pumping activity into InsP3-sensitive Ca 2+ 
stores [8,13]. The growth inhibitory effect of thapsigargin was 
relieved only after washout of thapsigargin and refilling of 
IP3-sensitive Ca 2÷ stores [10]. In contrast, when thapsigargin 
was added to actively proliferating cells 24 h after growth stim- 
ulation, the growth inhibitory effect of thapsigargin was sub- 
stantially reduced [8]. These findings led the authors to the 
conclusion that a specific cell cycle event necessary for the 
G0/G1 transition depends upon signals generated from func- 
tional InsP3-sensitive Ca 2÷ stores [9,10]. However, a question 
*Corresponding author. Fax: (81) (3) 5800 6845. 
Human foetal ung-derived iploid fibroblasts IMR-90 were main- 
tained at subconfluent state in Dulbecco's modified Eagle's medium 
(DMEM) containing 10% foetal calf serum as described [14]. Before 
each experiment confluent cultures were deprived of serum for 2 days 
in DMEM containing 0.2% bovine serum albumin and made quiescent 
[14]. Cells were growth-stimulated bychanging this medium to fresh 
growth media (0 time point). Thapsigargin (Sigma) was added to cells 
at indicated points. [3H]Thymidine incorporation i to DNA was meas- 
ured by pulse-labeling ofcells with 2/.tCi/ml of [3H-methyl]thymidine 
during the last 1 h of cell incubations, followed by counting of radioac- 
tivity incorporated into acid-precipitable material [14]. Measurement of
histone H1 kinase activity associated with p33 cDKz and Western blot 
analysis of p33 cDKz were performed by using a polyclonal antibody 
raised against asynthetic peptide corresponding to the carboxyl termi- 
nal sequence of human p33 cDK2 as described in detail elsewhere [15]. 
Western blot analyses of cyclin A and cyclin D1 were performed by 
using rabbit polyclonal ntibodies raised against the carboxyl terminal 
sequence of human cyclin A (UBI) and human cyclin D1 (Medical and 
Biological Laboratories, Nagoya, Japan), respectively. 
3. Results and discussion 
Stimulation of quiescent IMR-90 cells with 10% foetal calf 
serum resulted in the initiation of DNA synthesis after the G1 
period of 12-14 h [14]. As shown in Fig. 1A, when thapsigargin 
was added just prior to the addition of serum, it dose-depen- 
dently inhibited DNA synthesis with the ECso value of approx- 
imately 10 nM, which is comparable to that reported for 
DDT I MF-2 smooth muscle cells (20 nM) [8]. Thapsigargin had 
no effect on cell viability or morphology. To examine whether 
or not thapsigargin blocks cell cycle progression at steps later 
than the G0/G1 border, we added thapsigargin atvarious time 
points after serum addition (= zero time point) and measured 
DNA synthesis at 22 h (Fig. 1B). Thapsigargin similarly and 
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Fig. 1. A. The thapsigargin dose-response curve for inhibition of DNA 
synthesis nIMR-90 human diploid fibroblasts. Various concentrations 
of thapsigargin were added just before serum stimulation, and [3H]thy- 
midine incorporation i to DNA was measured after 22 h. B. Thapsi- 
gargin completely inhibits DNA synthesis when it is added to serum- 
stimulated cells at any time point in the G1 phase and even just before 
the G1/S boundary. Thapsigargin (0.1 gM) (TG) was added to cells at 
indicated times (h) after serum stimulation and [3H]thymidine incorpo- 
ration was measured at 22 h. Data represent the mean + S.E. of three 
determinations. Bars are absent where the S.E. value is smaller than half 
the size of the symbol (A) or the width of the line (B). 
completely inhibited DNA synthesis when it was introduced to 
cultures at either 0, 3, 6 or 10 h after serum stimulation. When 
thapsigargin was added to cells either 13 or 18 h after serum 
stimulation, i.e. the time points that correspond to the G1/S 
boundary and the early S phase, respectively, it still very 
strongly inhibited serum-stimulated DNA synthesis, though to 
lesser extents as compared to earlier additions. These results 
clearly indicate that thapsigargin completely blocks entry into 
the S phase when it is added to cells at any time point in the 
GI phase and, most notably, even just before the initiation of 
DNA synthesis. 
Recent studies have revealed that cell cycle is driven by se- 
quential activation of a family of cyclin-dependent kinases 
(CDKs) [16]. CDK2/cyclin A complex has been demonstrated 
to be indispensable for entry into and progression through the 
S phase. Thus, p33CoKZ-associated kinase activity starts to rise 
just prior to the GI/S boundary and continues to increase 
throughout the S phase [15,17]. p33 cDK2 protein is readily de- 
tectable in quiescent cells and moderately increases as cells 
progress into the S phase [15,17]. In contrast, cyclin A is unde- 
tectable in the GO or the G1 phase, and is induced to be ex- 
pressed at the G1/S border, progressively accumulating along 
with the S phase progression [18]. The activation of CDK2 as 
an active kinase depends on both the complex formation with 
a cyclin subunit and phosphorylation at Thrl60 by CDK acti- 
vating kinase (CAK) I19-21 ]. Microinjection of antisense cyclin 
A cDNA or antibodies against either cyclin A or p33 c°~z has 
been shown to block completely the initiation of DNA synthe- 
sis [17,18,22,23]. In addition, it is reported that cyclin A and 
CDK2 colocalize at the site of DNA replication in S phase 
nucleus [24]. 
Based on these current understandings, we tested the possi- 
bility that thapsigargin might affect the activation of cyclin 
A/CDK2 complex as an underlying molecular mechanism for 
cell cycle block at the G1/S border. Indeed, as shown in Fig. 2, 
thapsigargin completely inhibited serum-induced activation of 
CDK2 kinase, with a dose-response relationship similar to that 
obtained for inhibition of DNA synthesis (see Fig. 1A). Impor- 
tantly, thapsigargin completely abolished the CDK2 kinase ac- 
tivation when it was added to cells as late as 10 h after serum 
stimulation, just like DNA synthesis. The inhibitory effect of 
thapsigargin was slightly attenuated when it was added at 13 h, 
i.e. at the beginning of the S phase. Thapsigargin did not at all 
directly inhibit the CDK2 kinase activity in vitro when it was 
introduced into kinase assay tubes, indicating that the target(s) 
of thapsigargin action resides in one or more steps of CDK2 
activation process in vivo. We then examined protein levels of 
p33 coK2 and cyclin A by Western blot analysis (Fig. 3). In 
serum-stimulated cells, as cells progressed into the S phase the 
protein level of p33 cDK2 gradually increased and the Thrl60- 
phosphorylated active form emerged, the latter being detected 
as a band with a higher mobility on electrophoresis [19]. Tha- 
psigargin-mediated inhibition of p33 coK2 kinase activation was 
associated with total disappearance of the Thr160- 
phosphorylated form of p33 coK2, but not detectable decrease 
in the amount of the major p33 coK2 band as compared to 
serum-stimulated control cells (Fig. 3, upper panel). More sig- 
nificantly, thapsigargin completely abolished the expression of 
cyclin A in serum-stimulated cells (Fig. 3, lower panel). Induc- 
tion of cyclin A was similarly abolished whether thapsigargin 
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Fig. 2. Thapsigargin completely inhibits the activation ofCDK2 kinase 
when it is added to cells just before the GI/S boundary. Thapsigargin 
(0.003 1 tiM) was added to cells at indicated time points (h) after serum 
stimulation and p33CDKLassociated histone H1 kinase activity was 
measured at 22 h. Thapsigargin up to I gM did not inhibit CDK2 
kinase activity in vitro when introduced into kinase assay tubes. 
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time points, even 10 h after serum stimulation that is just before 
the G1/S boundary. From these observations it was concluded 
that thapsigargin suppressed serum-induced activation of 
CDK2 kinase through mechanisms involving inhibitions of cy- 
clin A expression and CAK-mediated phosphorylation of
p33 cDm at Thrl60. In addition, thapsigargin hibited serum- 
induced increase in the amount of a G1 cyclin, cyclin D1, to a 
basal unstimulated level (Fig. 3, lower panel), raising a possibil- 
ity that thapsigargin hibits activation of other members of 
CDKs including CDK4 [16]. 
It is generally known that thapsigargin duces an increase 
in [Ca2÷]~. Therefore, it might be possible that the inhibitory 
effects of thapsigargin on GI/S progression were mediated 
through an increase in [Ca2+]~. To test this possibility, we stud- 
ied whether or not the Ca 2÷ ionophore ionomycin mimicked the 
effects of thapsigargin. Ionomycin (0.1 gM), when added 5 h 
after serum stimulation, barely affected [3H]thymidine incorpo- 
ration into DNA (4029 + 188 vs. 3833 + 75 cpm per well for 
serum-stimulated control vs. serum-stimulated, ionomycin- 
treated cells, mean + S.D. from three determinations). Under 
the same experimental condition, ionomycin did not inhibit he 
expression level of either cyclin A or cyclin D1 (Fig. 4). The 
results clearly indicate that depletion of InsP3-sensitive Ca 2÷ 
stores, but not mobilization of Ca 2÷ itself, is responsible for 
thapsigargin-induced ll cycle arrest at the GI /S  boundary. 
Ghosh et al. [8] previously reported that the addition of 3 pM 
thapsigargin toDDT 1 MF-2 cells at the G0/G1 border educed 
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Fig. 3. (Upper panel) Thapsigargin does not suppress an increase in the 
protein level of CDK2, but completely inhibits CDK2 phosphorylation 
at Thrl60 in serum-stimulated c lls. Cells were incubated with serum 
for indicated time periods (h). Thapsigargin (0.1 pM) was added to- 
gether with serum where indicated. Anti-p33 cDK2 immunoprecipitate 
was resolved by electrophoresis, followed by Western blotting. Posi- 
tions of the major 33 kDa band (a long arrow) and the Thrl60- 
phosphorylated form (a short arrow and a dot) are indicated. (Lower 
panel) Thapsigargin completely inhibits induction of cyclins A and D 1 
in serum-stimulated c lls. Cells were incubated in the presence or ab- 
sence of serum for 21 h. Thapsigargin (0.1 pM) was added at indicated 
time points (h) after serum stimulation. Seventy microgram of cellular 
protein was analyzed by Western blotting for cellular content of cyclins 
A and D1, the positions of which are indicated by arrows. 
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Fig. 4. Ca 2+ mobilizing ionomycin does not inhibit serum-induced x- 
pression of cyclins A and D1. Thapsigargin (TG) or ionomycin (IM) 
at 0.1 gM each was added 5 h after serum stimulation and cell lysate 
was obtained at 21 h for Western blot analysis. 
the incorporation of [3H]methionine to cellular proteins by 70% 
after 56 h. We have also observed that 0.1 to 1/.tM of thapsi- 
gargin suppressed serum-induced increase in the cellular pro- 
tein content by approximately 60%. It is indeed suggested that 
Ca 2÷ inside endoplasmic reticulum plays a role in translation, 
processing and trafficking of certain proteins [25]. However, it 
is remarkable to note that, in a T lymphocyte cell line Jurkat 
cells, thapsigargin, in combination with a phorbol ester, in- 
duced a prominent increase in the synthesis of interleukin-2, in 
the face of depletion of InsP3-sensitive Ca 2+ stores [26]. Never- 
theless, thapsigargin plus a phorbol ester failed to stimulate 
proliferation i  this case. These observations strongly suggest 
that Ca 2+ filling inside InsP3-sensitive Ca 2. stores, which in- 
clude endoplasmic reticulum, is critical for growth factor-in- 
duced expression of a subset of cellular proteins, but not others. 
Our findings clearly show that cyclins A and D1, but not 
CDK2, are included in the former category. 
In summary, the present study demonstrates crucial involve- 
ment of Ca2+-filled InsP3-sensitive stores in cell cycle progres- 
sion throughout the G1 phase and especially just before the 
GI/S transition point. In addition, Ca 2+ inside nuclear envelope 
might also play a role in cell cycle progression, since the Ca 2+ 
pump on the outer leaflet of nuclear envelope is reportedly 
identical to the endoplasmic reticulum Ca 2+ pump [27]. 
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